









Markets
/
Stocks
/
nasdaq-tnya
/

Tenaya Therapeutics Inc

TNYA

1.290USD

+0.070+5.74%

Market hours （ET）Quotes delayed by 15 min

210.24MMarket Cap

LossP/E TTM



Tenaya Therapeutics Inc

1.290

+0.070+5.74%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

222 / 507

Overall Ranking

398 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

10.143

Target Price

+704.99%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.

Fairly Valued

The company’s latest PE is -1.30, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 93.48M shares, increasing 17.79% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 4.76M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.22.

Financial Health

Currency: USD Updated：2025-09-17

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.30, which is -16.69% below the recent high of -1.08 and -48.91% above the recent low of -1.94.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 222/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.44, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Tenaya Therapeutics Inc is 5.00, with a high of 40.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

10.143

Target Price

+731.38%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Tenaya Therapeutics Inc

TNYA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.37, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 1.42 and the support level at 1.04, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.88

Change

-0.51

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.034

Neutral

RSI(14)

56.826

Neutral

STOCH(KDJ)(9,3,3)

33.825

Sell

ATR(14)

0.104

Low Volatility

CCI(14)

6.537

Neutral

Williams %R

55.263

Sell

TRIX(12,20)

1.420

Buy

StochRSI(14)

3.259

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.232

Buy

MA10

1.275

Buy

MA20

1.202

Buy

MA50

0.961

Buy

MA100

0.745

Buy

MA200

1.002

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 57.36%, representing a quarter-over-quarter increase of 52.20%. The largest institutional shareholder is The Vanguard, holding a total of 4.76M shares, representing 2.92% of shares outstanding, with 29.36% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Column Group LP

49.31M

+424.60%

The Vanguard Group, Inc.

Star Investors

4.08M

+24.75%

Empery Asset Management, L.P.

8.73M

BlackRock Institutional Trust Company, N.A.

4.95M

-1.04%

Renaissance Technologies LLC

Star Investors

1.54M

AQR Capital Management, LLC

775.66K

Geode Capital Management, L.L.C.

1.38M

+8.39%

Euclidean Capital, L.L.C.

1.02M

Alphabet, Inc.

915.71K

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 2.97, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 3.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.